Welcome to our dedicated page for Edgewise Therapeutics SEC filings (Ticker: EWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edgewise Therapeutics, Inc. filings document a late-stage clinical biopharmaceutical company developing treatments for severe muscle diseases, including programs for muscular dystrophies and serious cardiac conditions. Form 8-K reports furnish quarterly and annual financial results, Regulation FD clinical-program disclosures, and material governance events.
The company’s proxy materials describe board structure, director elections, executive compensation, equity-award information, stockholder voting matters, and governance practices. Other disclosed matters include officer appointments, director appointments, compensatory arrangements, exhibits to earnings releases, and operating context for a development-stage drug pipeline.
Edgewise Therapeutics, Inc. President and CEO Kevin Koch reported multiple equity transactions on August 12, 2026. Previously granted RSUs converted into 17,969 and 21,875 shares of common stock, with a total of 17,971 shares sold in “sell-to-cover” trades solely to satisfy statutory tax withholding obligations, not as discretionary sales. Koch also received new awards of 100,000 RSUs, vesting in four annual installments beginning August 12, 2027, and 200,000 stock options with a $43.56 exercise price, vesting monthly over four years starting September 12, 2026.
RA Capital Management, L.P. and affiliated parties report a significant stake in Edgewise Therapeutics, Inc. As of June 30, 2026, RA Capital Healthcare Fund, L.P. directly holds 8,392,730 shares of Edgewise common stock. Based on 107,776,380 shares outstanding, this represents 7.8% of the company’s common stock.
RA Capital, as investment adviser to the Fund, has been delegated sole authority to vote and dispose of these shares, giving the Reporting Persons shared voting and dispositive power over 8,392,730 shares and no sole power. The Fund, RA Capital, Peter Kolchinsky, and Rajeev Shah each disclaim beneficial ownership except as required to determine their reporting obligations under Section 13(d) of the Exchange Act.
Edgewise Therapeutics, Inc. has a significant shareholder group led by Paradigm BioCapital entities and Senai Asefaw, M.D., reporting beneficial ownership of the company’s common stock as of June 30, 2026. Paradigm BioCapital Advisors LP, its general partner Paradigm BioCapital Advisors GP LLC, and Senai Asefaw may each be deemed to beneficially own 10,215,455 shares of common stock, representing 9.5% of the class, based on 107,593,006 shares outstanding as of April 30, 2026.
Paradigm BioCapital International Fund Ltd. directly holds 8,961,631 shares, or 8.3% of the common stock, with additional shares held in one or more separately managed accounts advised by Paradigm BioCapital Advisors LP. Each reporting party has sole voting and dispositive power over its reported shares and disclaims beneficial ownership of any shares beyond those directly held.
Baker Bros. Advisors LP and related parties filed Amendment No. 2 reporting their beneficial ownership in Edgewise Therapeutics, Inc. common stock. They collectively beneficially own 3,701,719 shares of common stock held through Baker Brothers Life Sciences, L.P. and 667, L.P.
This position represents 3.4% of Edgewise’s common stock, based on 107,776,380 shares outstanding as of June 30, 2026, as reported in the company’s Form 10-Q. The reporting persons have sole voting and dispositive power over these 3,701,719 shares and no shared voting or dispositive power, and they state that they now hold 5% or less of the class.
FMR LLC, a Delaware entity, and Abigail P. Johnson report beneficial ownership of common stock of Edgewise Therapeutics Inc. FMR LLC has sole voting power over 5,488,696 shares and sole dispositive power over 5,489,135 shares of common stock, representing 5.1% of the class as of June 30, 2026.
Abigail P. Johnson is reported as having sole dispositive power over the same 5,489,135 shares and no voting power. One or more other persons have rights to receive dividends or sale proceeds from these shares, but no such person has an interest exceeding 5% of Edgewise Therapeutics’ outstanding common stock. Certain subsidiaries involved are identified in an attached Exhibit 99.
Edgewise Therapeutics, Inc. reported a net loss of $57.3 million for the three months and $106.3 million for the six months ended June 30, 2026, wider than a year earlier as it increased investment in its pipeline. Research and development expenses rose to $47.5 million in the quarter, driven by EDG-7500 and EDG-15400 clinical activities and higher personnel costs, while general and administrative expenses grew to $14.4 million on commercial readiness and transaction-related spending.
As of June 30, 2026, Edgewise held $460.7 million in cash, cash equivalents and marketable securities. On July 10, 2026 it closed the Sevasemten Sale to Servier, receiving $1,550 million in upfront cash and eligibility for up to $1,100 million in additional milestones, for aggregate potential consideration of $2,650 million. Management states that existing cash plus the upfront proceeds are expected to fund operations for at least 12 months while advancing lead cardiovascular programs EDG-7500 and EDG-15400.
Edgewise Therapeutics reported second quarter 2026 results and detailed a major portfolio shift. In July 2026 it completed the sale of sevasemten and its muscular dystrophy business to Servier for $1.55 billion in upfront cash and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. Cash, cash equivalents and marketable securities were $460.7 million as of June 30, 2026; adding the upfront proceeds from the sale yields a pro forma balance of $2,010.7 million before taxes and transaction-related costs.
The company highlighted positive 12-week Phase 2 CIRRUS-HCM data for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy and plans to initiate a Phase 3 trial in the fourth quarter of 2026. EDG-15400 completed a Phase 1 study in healthy adults, with a Phase 2 trial in heart failure with preserved ejection fraction expected in the second half of 2026. Research and development expenses were $47.5 million and general and administrative expenses were $14.4 million, contributing to a net loss of $57.3 million, or $0.53 per share, for the quarter. Following the Servier transaction, Edgewise describes itself as a cardiovascular-focused company advancing EDG-7500, EDG-15400 and EDG-003.
Edgewise Therapeutics director Jonathan D. Root received a grant of stock options to acquire 16,377 shares of common stock on June 5, 2026. The options have an exercise price of $35.5900 per share and expire on June 5, 2036. According to the grant terms, 100% of the options vest on the earlier of June 5, 2027 or the business day prior to the 2027 annual meeting of shareholders, and Root now directly holds options for 16,377 shares from this grant.
Edgewise Therapeutics, Inc. completed the sale of its sevasemten muscular dystrophy program to Servier Pharmaceuticals LLC and Les Laboratoires Servier, receiving $1.55 billion in upfront cash and eligibility for up to $1.1 billion in additional regulatory and commercial milestones, for total potential consideration of $2.65 billion. The disposed assets are treated as a sale of nonfinancial assets under U.S. GAAP and do not qualify as discontinued operations. Edgewise has prepared unaudited pro forma condensed financial information under Article 11 of Regulation S-X to illustrate the effects.
Pro forma as of March 31, 2026, cash and cash equivalents rise to about $1.53 billion, total assets to $2.01 billion, and stockholders’ equity to roughly $1.75 billion, driven by an estimated pre-tax gain of $1,487,621 thousand and after-tax gain of $1,261,765 thousand. For 2025, pro forma results show net income of $1,135,527 thousand and earnings per share of $11.03, compared with a historical net loss of $167,795 thousand and a loss per share of $(1.63). For the three months ended March 31, 2026, the pro forma net loss is $27,937 thousand versus a historical loss of $49,013 thousand, reflecting removal of sevasemten-related expenses.
A Transition Services Agreement requires Edgewise to provide specified services to Servier at below-market rates; $17,880 thousand of consideration is allocated to this obligation and recorded as deferred income, with $5,364 thousand current and $12,516 thousand non-current, recognized in other income as services are performed. The pro forma statements present TSA costs in operating expenses and Servier reimbursements plus deferred income amortization in other income, with no net effect on pro forma earnings for the periods shown.